Stem cells could save sight after chemical burns

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Unilateral or bilateral chemical burn of the ocular surface * Severe ocular chemical burn of at least one eye, classified as stage VI according to the Dua severity classification (involving the entire limbus and conjunctiva) * Time from chemical injury to enrollment ≤ 15 days * Patient has received full study information and has provided written informed consent * Affiliated with or beneficiary of a social security or health insurance system Exclusion Criteria: * Imminent corneal perforation (loss of more than two-thirds of corneal thickness) * Ocular infection * Eyelid tissue loss with permanent corneal exposure * Known allergy or hypersensitivity to human albumin preparations * History of total or partial limbal stem cell deficiency prior to the chemical injury * Uncontrolled glaucoma prior to the ocular burn * Recipient of a solid organ or cell transplant * Severe or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, psychiatric, or cardiac disease, or any uncontrolled intercurrent illness * Active infection, including chronic or localized infections * History of malignancy (except completely resected localized basal cell carcinoma of the skin or cervical carcinoma in situ) within the past 5 years, whether treated or untreated, with or without evidence of recurrence or metastasis at screening * Current treatment with systemic immunosuppressive medications (including systemic corticosteroids, TNF-α antagonists, azathioprine, methotrexate, mycophenolate mofetil) * Adults under legal protection, individuals deprived of liberty by judicial or administrative decision, individuals receiving compulsory psychiatric care, or individuals admitted to a health or social care institution for purposes other than research * Pregnant or breastfeeding women * Women of childbearing potential who do not agree to use effective contraception throughout the study period (up to 12 months after the last injection) * Participation in another interventional clinical trial during the study follow-up period